DT2216

DRUG2 trials

Sponsors

Dialectic Therapeutics, Inc, Elizabeth Stover, MD, PhD

Conditions

Hematologic MalignancyOvarian CancerOvarian CarcinomaRecurrent Ovary CancerRecurrent Platinum-Resistant Ovarian CarcinomaSolid Tumor

Phase 1

A Study of DT2216 in Relapsed/Refractory Malignancies

CompletedNCT04886622

Dialectic Therapeutics, IncHematologic Malignancy, Solid Tumor

Start: 2021-08-25End: 2024-06-30Updated: 2025-04-16

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

RecruitingNCT06964009

Elizabeth Stover, MD, PhDOvarian Cancer, Ovarian Carcinoma, Recurrent Ovary Cancer +1

Start: 2025-09-22End: 2028-12-31Target: 30Updated: 2026-09-11

Related Papers

First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.

2025-11-12

Abstract B004: Phase 1b trial of BCL-XL degrader DT2216 and weekly paclitaxel in recurrent platinum-resistant ovarian cancer

Molecular Cancer Therapeutics2025-10-22

Abstract A026: Combination strategies with BCL-XL inhibition or degradation in ovarian clear cell carcinoma

Cancer Research2025-09-19

Abstract CT063: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies (NCT04886622)

Cancer Research2025-04-253 citations

Abstract 3888: Targeting Bcl-xL in fibrolamellar hepatocellular carcinoma

Cancer Research2022-06-15